Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia (MyeloConcept)
A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer
Sponsor: Myelo Therapeutics GmbH
Listed as NCT02692742, this PHASE2 trial focuses on Breast Cancer and Chemotherapy-Induced Neutropenia and remains completed. Sponsored by Myelo Therapeutics GmbH, it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Myelo Therapeutics GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Aurich, Germany , Dresden, Germany , Erlangen, Germany , Esslingen am Neckar, Germany , Frankfurt a.M., Germany , Friedrichshafen, Germany , Goslar, Germany , Hamburg, Germany , Hanover, Germany and 9 more locations